WO2005087920A3 - Recombinant chondroitinase abc i and uses thereof - Google Patents

Recombinant chondroitinase abc i and uses thereof Download PDF

Info

Publication number
WO2005087920A3
WO2005087920A3 PCT/US2005/008194 US2005008194W WO2005087920A3 WO 2005087920 A3 WO2005087920 A3 WO 2005087920A3 US 2005008194 W US2005008194 W US 2005008194W WO 2005087920 A3 WO2005087920 A3 WO 2005087920A3
Authority
WO
WIPO (PCT)
Prior art keywords
chondroitinase abc
treating
gags
enzymes
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/008194
Other languages
French (fr)
Other versions
WO2005087920A2 (en
Inventor
Vikas Prabhakar
Ishan Capila
Rahul Raman
Carlos Bosques
Kevin Pojasek
Ram Sasisekharan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Institute of Technology
Original Assignee
Massachusetts Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Institute of Technology filed Critical Massachusetts Institute of Technology
Priority to CA002558984A priority Critical patent/CA2558984A1/en
Priority to EP05735137A priority patent/EP1737954A2/en
Publication of WO2005087920A2 publication Critical patent/WO2005087920A2/en
Publication of WO2005087920A3 publication Critical patent/WO2005087920A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to chondroitinase ABC I and uses thereof. In particular, the invention relates to recombinant and modified chondroitinase ABC I, their production and their uses. The chondroitinase ABC I enzymes of the invention are useful for a variety of purposes, including degrading and analyzing polysaccharides such as glycosaminoglycans (GAGs). These GAGs can include chondroitin sulfate, dermatan sulfate, unsulfated chondroitin and hyaluronan. The chondroitinase ABC I enzymes can also be used in therapeutic methods such as promoting nerve regeneration, promoting stroke recovery, treating spinal cord injury, treating epithelial disease, treating infections and treating cancer.
PCT/US2005/008194 2004-03-10 2005-03-10 Recombinant chondroitinase abc i and uses thereof Ceased WO2005087920A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA002558984A CA2558984A1 (en) 2004-03-10 2005-03-10 Recombinant chondroitinase abc i and uses thereof
EP05735137A EP1737954A2 (en) 2004-03-10 2005-03-10 Recombinant chondroitinase abc i and uses thereof

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US55223204P 2004-03-10 2004-03-10
US60/552,232 2004-03-10
US57891704P 2004-06-10 2004-06-10
US60/578,917 2004-06-10
US62505204P 2004-11-03 2004-11-03
US60/625,052 2004-11-03

Publications (2)

Publication Number Publication Date
WO2005087920A2 WO2005087920A2 (en) 2005-09-22
WO2005087920A3 true WO2005087920A3 (en) 2006-02-02

Family

ID=34965511

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/008194 Ceased WO2005087920A2 (en) 2004-03-10 2005-03-10 Recombinant chondroitinase abc i and uses thereof

Country Status (4)

Country Link
US (5) US7507570B2 (en)
EP (1) EP1737954A2 (en)
CA (1) CA2558984A1 (en)
WO (1) WO2005087920A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7560106B2 (en) 1998-08-27 2009-07-14 Massachusetts Institute Of Technology Rationally designed heparinases derived from heparinase I and II and methods of sequencing therewith

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2370539C (en) * 1999-04-23 2009-01-06 Massachusetts Institute Of Technology System and method for notating polymers
CA2402160C (en) * 2000-03-08 2012-02-14 Massachusetts Institute Of Technology Heparinase iii and uses thereof
DE60138115D1 (en) * 2000-09-12 2009-05-07 Massachusetts Inst Technology METHOD AND PRODUCTS ASSOCIATED WITH LOW-MOLECULAR HEPARINE
AU2002224408B2 (en) 2000-10-18 2007-08-23 Massachusetts Institute Of Technology Methods and products related to pulmonary delivery of polysaccharides
CA2484604C (en) * 2002-05-03 2011-08-02 Massachusetts Institute Of Technology .delta. 4,5 glycuronidase and uses thereof
EP2301564A1 (en) 2002-05-04 2011-03-30 Acorda Therapeutics, Inc. Compositions and methods for promoting neuronal outgrowth
JP4657726B2 (en) 2002-05-20 2011-03-23 マサチューセッツ インスティテュート オブ テクノロジー A novel method for sequencing using NMR
US20060153827A1 (en) * 2002-08-15 2006-07-13 Gruskin Elliott A Chimeric protein
JP4606712B2 (en) 2003-01-08 2011-01-05 マサチューセッツ インスティテュート オブ テクノロジー 2-O sulfatase compositions and related methods
JP4754492B2 (en) * 2003-05-16 2011-08-24 アコーダ セラピューティクス、インク． Compositions and methods for treating central nervous system disorders
US7959914B2 (en) 2003-05-16 2011-06-14 Acorda Therapeutics, Inc. Methods of reducing extravasation of inflammatory cells
EP3514238B1 (en) 2003-05-16 2021-05-05 Acorda Therapeutics, Inc. Proteoglycan degrading mutants for treatment of cns
EP1737954A2 (en) 2004-03-10 2007-01-03 The Massachusetts Institute Of Technology Recombinant chondroitinase abc i and uses thereof
US20060057638A1 (en) * 2004-04-15 2006-03-16 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
US20060127950A1 (en) 2004-04-15 2006-06-15 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
US8226941B2 (en) * 2004-05-18 2012-07-24 Acorda Therapeutics, Inc. Methods of purifying chondroitinase and stable formulations thereof
US8765122B2 (en) * 2004-06-14 2014-07-01 The Research Foundation Of State University Of New York Nanosphere/microsphere delivery system for the treatment of spinal cord injury
EP1768687A2 (en) 2004-06-29 2007-04-04 Massachusetts Institute Of Technology Methods and compositions related to the modulation of intercellular junctions
US20060154894A1 (en) * 2004-09-15 2006-07-13 Massachusetts Institute Of Technology Biologically active surfaces and methods of their use
JP5189985B2 (en) 2005-09-26 2013-04-24 アコーダ セラピューティクス、インク． Composition using chondroitinase ABCI mutant and method of using the same
WO2007120478A2 (en) * 2006-04-03 2007-10-25 Massachusetts Institute Of Technology Glycomic patterns for the detection of disease
JP5279491B2 (en) * 2006-05-19 2013-09-04 愛知県 Brain damage improver
AU2014200000B2 (en) * 2006-10-10 2016-04-21 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase abci mutants
US7722864B2 (en) * 2006-10-10 2010-05-25 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase ABCI mutants
AU2016206267B2 (en) * 2006-10-10 2018-07-05 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase abci mutants
CA2674493C (en) 2007-01-05 2017-05-09 Massachusetts Institute Of Technology Compositions of and methods of using sulfatases from flavobacterium heparinum
GB0712302D0 (en) * 2007-06-22 2007-08-01 Cambridge Entpr Ltd Chrondroitinase polypeptides
US8450106B2 (en) * 2007-10-17 2013-05-28 The Ohio State University Research Foundation Oncolytic virus
US20090286289A1 (en) * 2008-03-10 2009-11-19 Pang Danny Z Production of Hyaluronate Unsaturated Disaccharides and its Application
US20140212404A1 (en) * 2012-11-14 2014-07-31 Khizer Khaderi Compositions and Methods for Treating Injuries to the Visual System of a Human
WO2014201220A1 (en) * 2013-06-12 2014-12-18 The Board Of Trustees Of The University Of Illinois Methods for detecting prostate cancer
WO2014202834A1 (en) 2013-06-18 2014-12-24 University Of Helsinki Protamine in treatment of neuronal injuries
US20160244740A1 (en) * 2013-09-27 2016-08-25 Ohio State Innovation Foundation Mutant chondroitinase abc i compositions and methods of their use
KR102167443B1 (en) * 2019-03-25 2020-10-19 주식회사 카티프라임 In vitro osteoarthritis condition model and drug screening method for osteoarthritis using the same
US20230091945A1 (en) * 2020-02-10 2023-03-23 The Governing Council Of The University Of Toronto Chondroitinase abc mutants and methods of manufacture and use thereof
CN111593040B (en) * 2020-06-20 2022-08-30 山东大学 Dermatan sulfate lyase and application thereof
CN116042593B (en) * 2023-01-16 2023-07-14 山东省农业科学院畜牧兽医研究所 Clostridium perfringens bacteriophage lyase and application thereof in preparation of clostridium perfringens infection resistant medicines

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0613949A2 (en) * 1993-02-24 1994-09-07 Maruha Corporation Gene encoding chondroitinase ABC and uses therefor
WO2003102160A2 (en) * 2002-06-03 2003-12-11 Massachusetts Institute Of Technology Rationally designed polysaccharide lyases derived from chondroitinase b

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US739904A (en) * 1902-08-05 1903-09-29 Orville Mcnorton Jr Music holder and turner.
ZA912770B (en) 1990-04-16 1992-01-29 Bethesda Eye Inst Enzymatic disinsertion of vitreous body
JPH04270327A (en) 1991-02-26 1992-09-25 Fuji Photo Optical Co Ltd Exposure correcting device for camera
US6001630A (en) 1992-06-26 1999-12-14 Seikagaku Kogyo Kabushiki Kaisha (Seikagaku Corporation) Pharmaceutical compositions of chondroitinase ABC isolated from Proteus vulgaris ATCC 6896
US5496718A (en) 1992-06-26 1996-03-05 Seikagaku Kogyo Kabushiki Kaisha (Seikagaku Corporation) Chondroitinase ABC isolated from proteus vulgaris ATCC 6896
US5773277A (en) 1992-06-26 1998-06-30 Seikagaku Kogyo Kabushiki Kaisha Crystalline chondroitinase isolated from Proteus vulgaris ATCC 6896
AU697156B2 (en) 1993-04-23 1998-10-01 American Cyanamid Company Cloning and expression of the chondroitinase I and II genes from (p. vulgaris)
US5578480A (en) 1993-04-23 1996-11-26 American Cyanamid Company Methods for the isolation and purification of the recombinantly expressed chondroitinase I and II enzymes from P. vulgaris
US5741692A (en) * 1994-04-22 1998-04-21 American Cyanamid Company Protein vulgaris chondroitinase II
US5498536A (en) * 1994-04-22 1996-03-12 American Cyanamid Company Chondroitinase II from Proteus vulgaris
US5525500A (en) 1994-04-22 1996-06-11 American Cyanamid Company Chromatographic process for the copurification of chondroitinase I and II proteins from Proteus vulgaris
US6093563A (en) 1994-07-08 2000-07-25 Ibex Technologies R And D, Inc. Chondroitin lyase enzymes
US5997863A (en) 1994-07-08 1999-12-07 Ibex Technologies R And D, Inc. Attenuation of wound healing processes
US5888798A (en) 1995-06-07 1999-03-30 American Cyanamid Company Chondroitinase I and chondroitinase II producing mutants of P. vulgaris
US6217863B1 (en) 1995-10-30 2001-04-17 Massachusetts Institute Of Technology Rationally designed polysaccharide lyases derived from heparinase I
EP0875253B1 (en) 1997-05-02 2005-04-06 Seikagaku Corporation Chondroitinase compositions
JP2000044601A (en) 1998-07-29 2000-02-15 Seikagaku Kogyo Co Ltd New galactosaminoglucan
US7056504B1 (en) 1998-08-27 2006-06-06 Massachusetts Institute Of Technology Rationally designed heparinases derived from heparinase I and II
JP2003527822A (en) 1998-08-27 2003-09-24 マサチューセッツ インスティテュート オブ テクノロジー Rationally designed heparinases derived from heparinase I and II
CA2370539C (en) 1999-04-23 2009-01-06 Massachusetts Institute Of Technology System and method for notating polymers
DE60040800D1 (en) 1999-11-17 2008-12-24 Biomarin Pharm Inc REDUCTION OF ANGIOGENESIS USING CHONDROITIN SULFATE OF REMAINING ENZYMES
CA2402160C (en) 2000-03-08 2012-02-14 Massachusetts Institute Of Technology Heparinase iii and uses thereof
US7094165B2 (en) * 2000-03-17 2006-08-22 Delbert Clarke Pile Apparatus and method for a retractable basketball backboard and hoop assembly
DE60138115D1 (en) 2000-09-12 2009-05-07 Massachusetts Inst Technology METHOD AND PRODUCTS ASSOCIATED WITH LOW-MOLECULAR HEPARINE
AU2002224408B2 (en) 2000-10-18 2007-08-23 Massachusetts Institute Of Technology Methods and products related to pulmonary delivery of polysaccharides
WO2002077199A2 (en) 2001-03-27 2002-10-03 Massachusetts Institute Of Technology Methods and products related to fgf dimerization
GB0205022D0 (en) 2002-03-04 2002-04-17 Univ Cambridge Tech Materials and methods for the treatment of cns damage
CA2484604C (en) 2002-05-03 2011-08-02 Massachusetts Institute Of Technology .delta. 4,5 glycuronidase and uses thereof
JP4657726B2 (en) 2002-05-20 2011-03-23 マサチューセッツ インスティテュート オブ テクノロジー A novel method for sequencing using NMR
JP4606712B2 (en) 2003-01-08 2011-01-05 マサチューセッツ インスティテュート オブ テクノロジー 2-O sulfatase compositions and related methods
EP3514238B1 (en) 2003-05-16 2021-05-05 Acorda Therapeutics, Inc. Proteoglycan degrading mutants for treatment of cns
EP1737954A2 (en) 2004-03-10 2007-01-03 The Massachusetts Institute Of Technology Recombinant chondroitinase abc i and uses thereof
US20060127950A1 (en) 2004-04-15 2006-06-15 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
WO2005110438A2 (en) 2004-04-15 2005-11-24 Massachusetts Institute Of Technology Methods and products related to the intracellular delivery of polysaccharides
US20060057638A1 (en) 2004-04-15 2006-03-16 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
EP1768687A2 (en) 2004-06-29 2007-04-04 Massachusetts Institute Of Technology Methods and compositions related to the modulation of intercellular junctions
US20060154894A1 (en) 2004-09-15 2006-07-13 Massachusetts Institute Of Technology Biologically active surfaces and methods of their use
CA2594013A1 (en) 2005-01-12 2006-07-20 Massachusetts Institute Of Technology Methods and compositions related to modulating the extracellular stem cell environment
US20090156477A1 (en) 2005-03-29 2009-06-18 Massachusetts Institute Of Technology Compositions and Methods for Regulating Inflammatory Responses
WO2006105313A2 (en) 2005-03-29 2006-10-05 Massachusetts Institute Of Technology Compositions of and methods of using oversulfated glycosaminoglycans
US7429373B2 (en) * 2005-06-24 2008-09-30 Air Products And Chemicals, Inc. Process for autothermal generation of hydrogen
WO2007120478A2 (en) 2006-04-03 2007-10-25 Massachusetts Institute Of Technology Glycomic patterns for the detection of disease
CA2674493C (en) 2007-01-05 2017-05-09 Massachusetts Institute Of Technology Compositions of and methods of using sulfatases from flavobacterium heparinum

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0613949A2 (en) * 1993-02-24 1994-09-07 Maruha Corporation Gene encoding chondroitinase ABC and uses therefor
WO2003102160A2 (en) * 2002-06-03 2003-12-11 Massachusetts Institute Of Technology Rationally designed polysaccharide lyases derived from chondroitinase b

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BRADBURY E J ET AL: "Chondroitinase ABC promotes regeneration and functional recovery following spinal cord injury", SOCIETY FOR NEUROSCIENCE ABSTRACTS, SOCIETY FOR NEUROSCIENCE, US, vol. 27, no. part 2, 2001, pages 1835, XP002244997, ISSN: 0190-5295 *
DENHOLM E M ET AL: "ANTI-TUMOR ACTIVITIES OF CHONDROITINASE AC AND CHONDROITINASE B: INHIBITION OF ANGIOGENESIS, PROLIFERATION AND INVASION", EUROPEAN JOURNAL OF PHARMACOLOGY, AMSTERDAM, NL, vol. 416, no. 3, 2001, pages 213 - 221, XP001002664, ISSN: 0014-2999 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7560106B2 (en) 1998-08-27 2009-07-14 Massachusetts Institute Of Technology Rationally designed heparinases derived from heparinase I and II and methods of sequencing therewith

Also Published As

Publication number Publication date
US7662604B2 (en) 2010-02-16
EP1737954A2 (en) 2007-01-03
US20070224670A1 (en) 2007-09-27
WO2005087920A2 (en) 2005-09-22
US20070202563A1 (en) 2007-08-30
US20070148157A1 (en) 2007-06-28
CA2558984A1 (en) 2005-09-22
US20070148740A1 (en) 2007-06-28
US8338119B2 (en) 2012-12-25
US7507570B2 (en) 2009-03-24
US7592152B2 (en) 2009-09-22
US20060078959A1 (en) 2006-04-13
US7553950B2 (en) 2009-06-30

Similar Documents

Publication Publication Date Title
WO2005087920A3 (en) Recombinant chondroitinase abc i and uses thereof
Karbownik et al. Hyaluronan: towards novel anti-cancer therapeutics
Smith et al. “GAG-ing with the neuron”: The role of glycosaminoglycan patterning in the central nervous system
WO2007070547A3 (en) Treatment of arthritis and other musculoskeletal disorders with crosslinked hyaluronic acid
US20080057091A1 (en) Compositions with several hyaluronic acid fractions for cosmetic use
WO2007084769A3 (en) Microalgae-derived compositions for improving the health and appearance of skin
WO2003102160A3 (en) Rationally designed polysaccharide lyases derived from chondroitinase b
WO2006071802A3 (en) Treatment of stroke and other acute neural degenerative disorders using postpartum derived cells
WO2007113222A3 (en) Immunogenic composition
WO2004065423A3 (en) Recognition molecules for the treatment and detection of tumours
PH12014501387B1 (en) Low anticoagulant heparins
WO2004000885A3 (en) Molecular weight reduction of polysaccharides by electron beams
WO2004062592A3 (en) 2-o sulfatase compositions and related methods
WO2006032500A3 (en) Immunogenic composition
WO2011056688A3 (en) Molecular profiling for personalized medicine
WO2005063820A3 (en) Il-7 fusion proteins
WO2010078036A3 (en) Biocompatible polysaccharide-based hydrogels
RU2017124620A (en) Vaccination of Cyclodextrin with Amide Bonds to Hyaluronic Acid Cross-Linked with Ether and Their Use
WO2007127298A3 (en) Pucoidans for reducing blood coagulation
US8202986B2 (en) Branched hyaluronic acid and method of manufacture
EP2772260A3 (en) Therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment
WO2006072243A1 (en) Hyaluronic acid fraction with moisturizing and anti-wrinkle properties
ITPD20050206A1 (en) BIOMATERIALS IN THE FORM OF FIBER TO BE USED AS MEDICAL DEVICES IN THE TREATMENT OF WOUNDS AND THEIR PROCESSES OF PRODUCTION
WO2007132292A3 (en) Therapy for alzheimer's disease
IL172477A0 (en) Viscosupplementation with algal polysaccharides in the treatment of arthritis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2558984

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: 2005735137

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005735137

Country of ref document: EP